Ranolazine (BioDeep_00000018478)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide

化学式: C24H33N3O4 (427.2470938000001)
中文名称: 雷诺嗪
谱图信息: 最多检出来源 Homo sapiens(blood) 0.14%

分子结构信息

SMILES: CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
InChI: InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)

描述信息

Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.
C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent
D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers
C - Cardiovascular system > C01 - Cardiac therapy
D049990 - Membrane Transport Modulators
C93038 - Cation Channel Blocker

同义名列表

14 个代谢物同义名

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide; Dihydrochloride, ranolazine; Ranolazine dihydrochloride; Hydrochloride, ranolazine; Ranolazine hydrochloride; Ranolazine 2HCL; HCL, Ranolazine; Ranolazine HCL; (-)-Ranolazine; RANOLAZINE; Renolazine; Ranexa



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Z Dogan, S Durmus, D D Ergun, R Gelisgen, H Uzun. Ranolazine exhibits anti-inflammatory and antioxidant activities in H9c2 cardiomyocytes. European review for medical and pharmacological sciences. 2023 04; 27(7):2953-2963. doi: 10.26355/eurrev_202304_31927. [PMID: 37070896]
  • Irene Lasheras-Otero, Iker Feliu, Alberto Maillo, Haritz Moreno, Marta Redondo-Muñoz, Paula Aldaz, Ana Bocanegra, Ana Olias-Arjona, Fernando Lecanda, Joaquin Fernandez-Irigoyen, Enrique Santamaria, Ignacio M Larrayoz, David Gomez-Cabrero, Claudia Wellbrock, Silvestre Vicent, Imanol Arozarena. The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in Melanoma. The Journal of investigative dermatology. 2023 Feb; 143(2):305-316.e5. doi: 10.1016/j.jid.2022.08.038. [PMID: 36058299]
  • Maria Vitoria da Silva, Artur Santos-Miranda, Julliane V Joviano-Santos, Diego Santos Souza, Leisiane Pereira Marques, Jaqueline Oliveira Sarmento, Samuel Santos Beserra, Danilo Roman-Campos. The insecticide β-Cyfluthrin induces acute arrhythmic cardiotoxicity through interaction with NaV1.5 and ranolazine reverses the phenotype. Clinical science (London, England : 1979). 2022 03; 136(5):329-343. doi: 10.1042/cs20211151. [PMID: 35190819]
  • Kerim Esenboğa, Alparslan Kurtul, Hüseyin Nazman, Cemre Gül Tekin, Nil Özyüncü, Türkan Seda Tan, Eralp Tutar, Sibel Tekin Turhan. Evaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Disease. Angiology. 2022 Jan; 73(1):73-78. doi: 10.1177/00033197211005590. [PMID: 33823622]
  • Marta Tomczyk, Alicja Braczko, Patrycja Jablonska, Adriana Mika, Kamil Przyborowski, Agata Jedrzejewska, Oliwia Krol, Filip Kus, Tomasz Sledzinski, Stefan Chlopicki, Ewa M Slominska, Ryszard T Smolenski. Enhanced Muscle Strength in Dyslipidemic Mice and Its Relation to Increased Capacity for Fatty Acid Oxidation. International journal of molecular sciences. 2021 Nov; 22(22):. doi: 10.3390/ijms222212251. [PMID: 34830135]
  • Matt Skinner, Ed Hale, Peter Ceuppens, Chris Pollard. Differentiating multichannel block on the guinea pig ECG: Use of Tpeak-Tend and J-Tpeak. Journal of pharmacological and toxicological methods. 2021 Sep; 111(?):107085. doi: 10.1016/j.vascn.2021.107085. [PMID: 34182121]
  • Pritikanta Paul, Rocio Vazquez Do Campo, Teerin Liewluck, Elie Naddaf. Ranolazine-induced lipid storage myopathy presenting with respiratory failure and head drop. Neuromuscular disorders : NMD. 2021 06; 31(6):546-550. doi: 10.1016/j.nmd.2021.03.004. [PMID: 33903020]
  • Chengdai Yuan, Wei Luo, Xiaocao Ren, Maxiao Ya, Wenlong Yan, Quanbin Hui. Ranolazine in the prevention and treatment of atrial fibrillation: A protocol for meta-analysis. Medicine. 2021 Apr; 100(16):e25437. doi: 10.1097/md.0000000000025437. [PMID: 33879675]
  • Thomas A Zelniker, David A Morrow, Benjamin M Scirica, Jeremy D Furtado, Jianping Guo, Dariush Mozaffarian, Marc S Sabatine, Michelle L O'Donoghue. Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. Journal of the American Heart Association. 2021 04; 10(8):e017401. doi: 10.1161/jaha.120.017401. [PMID: 33840228]
  • Dragan Opačić, Arne van Hunnik, Stef Zeemering, Arvinder Dhalla, Luiz Belardinelli, Ulrich Schotten, Sander Verheule. Electrophysiological effects of ranolazine in a goat model of lone atrial fibrillation. Heart rhythm. 2021 04; 18(4):615-622. doi: 10.1016/j.hrthm.2020.11.021. [PMID: 33232809]
  • Ugochukwu Chukwunyere, Ahmet Ozer Sehirli, Nurettin Abacioglu. COVID-19-related arrhythmias and the possible effects of ranolazine. Medical hypotheses. 2021 Apr; 149(?):110545. doi: 10.1016/j.mehy.2021.110545. [PMID: 33636586]
  • Chang Ma, Tongshuai Chen, Yun Ti, Yi Yang, Yan Qi, Chunmei Zhang, Lingxin Liu, Peili Bu. Ranolazine alleviates contrast-associated acute kidney injury through modulation of calcium independent oxidative stress and apoptosis. Life sciences. 2021 Feb; 267(?):118920. doi: 10.1016/j.lfs.2020.118920. [PMID: 33352171]
  • Amanda Guth, Emily Monk, Rajesh Agarwal, Bryan C Bergman, Karin A Zemski-Berry, Angela Minic, Kimberly Jordan, Isabel R Schlaepfer. Targeting Fat Oxidation in Mouse Prostate Cancer Decreases Tumor Growth and Stimulates Anti-Cancer Immunity. International journal of molecular sciences. 2020 Dec; 21(24):. doi: 10.3390/ijms21249660. [PMID: 33352903]
  • Hans Friedrich Stabenau, Changyu Shen, Larisa G Tereshchenko, Jonathan W Waks. Changes in global electrical heterogeneity associated with dofetilide, quinidine, ranolazine, and verapamil. Heart rhythm. 2020 03; 17(3):460-467. doi: 10.1016/j.hrthm.2019.09.017. [PMID: 31539628]
  • Hung-Yen Ke, Li-Han Chin, Chien-Sung Tsai, Feng-Zhi Lin, Yen-Hui Chen, Yung-Lung Chang, Shih-Ming Huang, Yao-Chang Chen, Chih-Yuan Lin. Cardiac calcium dysregulation in mice with chronic kidney disease. Journal of cellular and molecular medicine. 2020 03; 24(6):3669-3677. doi: 10.1111/jcmm.15066. [PMID: 32064746]
  • Houyong Zhu, Xiaoqun Xu, Xiaojiang Fang, Jianwu Zheng, Qian Zhao, Tielong Chen, Jinyu Huang. Response to Letter Regarding Article, "Effects of the Antianginal Drugs Ranolazine, Nicorandil and Ivabradine on Coronary Microvascular Function in Patients with Non-obstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials". Clinical therapeutics. 2020 02; 42(2):376-377. doi: 10.1016/j.clinthera.2019.12.016. [PMID: 31973937]
  • Velia Cassano, Antonio Leo, Martina Tallarico, Valentina Nesci, Antonio Cimellaro, Teresa Vanessa Fiorentino, Rita Citraro, Marta Letizia Hribal, Giovambattista De Sarro, Francesco Perticone, Giorgio Sesti, Emilio Russo, Angela Sciacqua. Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model. Nutrients. 2020 Jan; 12(2):. doi: 10.3390/nu12020382. [PMID: 32023991]
  • Alice Lee, Scott P Fraser, Mustafa B A Djamgoz. Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: Effects of combination with ranolazine. Journal of cellular physiology. 2019 12; 234(12):23066-23081. doi: 10.1002/jcp.28868. [PMID: 31222761]
  • Thomas A Marciniak, Victor Serebruany. Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers. The American journal of medicine. 2019 12; 132(12):e844-e845. doi: 10.1016/j.amjmed.2019.02.032. [PMID: 30871921]
  • Bridget A Scoville, Jonathan H Segal, Noha N Salama, Michael Heung, Barry E Bleske, Rachel F Eyler, Bruce A Mueller. Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. Renal failure. 2019 Nov; 41(1):118-125. doi: 10.1080/0886022x.2019.1585371. [PMID: 30909832]
  • Houyong Zhu, Xiaoqun Xu, Xiaojiang Fang, Jianwu Zheng, Qian Zhao, Tielong Chen, Jinyu Huang. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clinical therapeutics. 2019 10; 41(10):2137-2152.e12. doi: 10.1016/j.clinthera.2019.08.008. [PMID: 31548105]
  • Efe Eworuke, Emily C Welch, Anne Tobenkin, Judith C Maro. Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure. Drug safety. 2019 07; 42(7):897-906. doi: 10.1007/s40264-019-00798-2. [PMID: 30734242]
  • Tjark F Schwemer, Navina Deutscher, Nadine Diermann, Rainer Böger, Edzard Schwedhelm, Stefan Blankenberg, Felix W Friedrich. Effect of ranolazine on plasma arginine derivatives and urinary isoprostane 8-iso-PGF2α in patients with myocardial infarction in the randomized RIMINI-Trial. Scientific reports. 2019 04; 9(1):5708. doi: 10.1038/s41598-019-42239-1. [PMID: 30952941]
  • S Teng, Z Ren, K Zhao. Vagal Stimulation Facilitates Improving Effects of Ranolazine on Cardiac Function in Rats with Chronic Ischemic Heart Failure. Current molecular medicine. 2018; 18(1):36-43. doi: 10.2174/1566524018666180608085330. [PMID: 29879885]
  • Iacopo Olivotto, Paolo G Camici, Piera Angelica Merlini, Claudio Rapezzi, Monica Patten, Vicent Climent, Gianfranco Sinagra, Benedetta Tomberli, Francisco Marin, Philipp Ehlermann, Lars S Maier, Alessandra Fornaro, Claudius Jacobshagen, Antonello Ganau, Luciano Moretti, Antonio Hernandez Madrid, Raffaele Coppini, Giorgio Reggiardo, Corrado Poggesi, Francesco Fattirolli, Luiz Belardinelli, Gianfranco Gensini, Alessandro Mugelli. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. Circulation. Heart failure. 2018 01; 11(1):e004124. doi: 10.1161/circheartfailure.117.004124. [PMID: 29321131]
  • Raffaele Coppini, Luca Mazzoni, Cecilia Ferrantini, Francesca Gentile, Josè Manuel Pioner, Annunziatina Laurino, Lorenzo Santini, Valentina Bargelli, Matteo Rotellini, Gianluca Bartolucci, Claudia Crocini, Leonardo Sacconi, Chiara Tesi, Luiz Belardinelli, Jil Tardiff, Alessandro Mugelli, Iacopo Olivotto, Elisabetta Cerbai, Corrado Poggesi. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. Circulation. Heart failure. 2017 03; 10(3):. doi: 10.1161/circheartfailure.116.003565. [PMID: 28255011]
  • Ravi B Patel, Sara Tannenbaum, Ana Viana-Tejedor, Jianping Guo, KyungAh Im, David A Morrow, Benjamin M Scirica. Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. European heart journal. Acute cardiovascular care. 2017 Feb; 6(1):18-25. doi: 10.1177/2048872615624241. [PMID: 26714972]
  • ". Shedding Light on Fat Dependence in AML. Cancer discovery. 2016 12; 6(12):OF8. doi: 10.1158/2159-8290.cd-nb2016-128. [PMID: 27920142]
  • Dmitry O Koltun, Eric Q Parkhill, Elfatih Elzein, Tetsuya Kobayashi, Robert H Jiang, Xiaofen Li, Thao D Perry, Belem Avila, Wei-Qun Wang, Ryoko Hirakawa, Catherine Smith-Maxwell, Lin Wu, Arvinder K Dhalla, Sridharan Rajamani, Nevena Mollova, Brian Stafford, Jennifer Tang, Luiz Belardinelli, Jeff A Zablocki. Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine. Bioorganic & medicinal chemistry letters. 2016 07; 26(13):3207-3211. doi: 10.1016/j.bmcl.2016.03.096. [PMID: 27038498]
  • Omar T Hassan, Reem T Hassan, Rohit R Arora. Organic Cation Transporter-Mediated Clearance of Cardiovascular Drugs: A Pharmacological Perspective. American journal of therapeutics. 2016 May; 23(3):e855-61. doi: 10.1097/mjt.0000000000000148. [PMID: 25259955]
  • Frederik Flenner, Felix W Friedrich, Nele Ungeheuer, Torsten Christ, Birgit Geertz, Silke Reischmann, Stefan Wagner, Konstantina Stathopoulou, Klaus-Dieter Söhren, Florian Weinberger, Edzard Schwedhelm, Friederike Cuello, Lars S Maier, Thomas Eschenhagen, Lucie Carrier. Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy. Cardiovascular research. 2016 Jan; 109(1):90-102. doi: 10.1093/cvr/cvv247. [PMID: 26531128]
  • Mardi Gomberg-Maitland, Robert Schilz, Anuj Mediratta, Karima Addetia, Sandra Coslet, Vasiliki Thomeas, Hunter Gillies, Ronald J Oudiz. Phase I safety study of ranolazine in pulmonary arterial hypertension. Pulmonary circulation. 2015 Dec; 5(4):691-700. doi: 10.1086/683813. [PMID: 26697176]
  • Jose Vicente, Lars Johannesen, Jay W Mason, William J Crumb, Esther Pueyo, Norman Stockbridge, David G Strauss. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. Journal of the American Heart Association. 2015 Apr; 4(4):. doi: 10.1161/jaha.114.001615. [PMID: 25870186]
  • Shama Ahmad, Aftab Ahmad, Tara B Hendry-Hofer, Joan E Loader, William C Claycomb, Olivier Mozziconacci, Christian Schöneich, Nichole Reisdorph, Roger L Powell, Joshua D Chandler, Brian J Day, Livia A Veress, Carl W White. Sarcoendoplasmic reticulum Ca(2+) ATPase. A critical target in chlorine inhalation-induced cardiotoxicity. American journal of respiratory cell and molecular biology. 2015 Apr; 52(4):492-502. doi: 10.1165/rcmb.2014-0005oc. [PMID: 25188881]
  • Charles D Kassardjian, Xia Tian, Georgirene Vladutiu, Lee-Jun Wong, Margherita Milone. Myopathy during treatment with the antianginal drug ranolazine. Journal of the neurological sciences. 2014 Dec; 347(1-2):380-2. doi: 10.1016/j.jns.2014.10.037. [PMID: 25466697]
  • Francesca Fumagalli, Ilaria Russo, Lidia Staszewsky, Yongqin Li, Teresa Letizia, Serge Masson, Deborah Novelli, Marcella Rocchetti, Mara Canovi, Pietro Veglianese, Marco Gobbi, Roberto Latini, Antonio Zaza, Giuseppe Ristagno. Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest. Heart rhythm. 2014 Sep; 11(9):1641-7. doi: 10.1016/j.hrthm.2014.05.023. [PMID: 24858811]
  • Iordanis Mourouzis, Polixeni Mantzouratou, Georgios Galanopoulos, Erietta Kostakou, Arvinder K Dhalla, Luiz Belardinelli, Constantinos Pantos. The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats. Journal of cardiovascular pharmacology and therapeutics. 2014 Sep; 19(5):457-69. doi: 10.1177/1074248414524481. [PMID: 24651516]
  • June-Wha Rhee, Stephen D Wiviott, Benjamin M Scirica, C Michael Gibson, Sabina A Murphy, Marc P Bonaca, David A Morrow, Jessica L Mega. Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. Clinical cardiology. 2014 Jun; 37(6):350-6. doi: 10.1002/clc.22253. [PMID: 24481910]
  • Liang Guo, Luke Coyle, Rory M C Abrams, Raymond Kemper, Eric T Chiao, Kyle L Kolaja. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicological sciences : an official journal of the Society of Toxicology. 2013 Dec; 136(2):581-94. doi: 10.1093/toxsci/kft205. [PMID: 24052561]
  • P Ravindra Babu, K Naveen Babu, P L Haroled Peter, K Rajesh, P Jawahar Babu. Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. Drug development and industrial pharmacy. 2013 Jun; 39(6):873-9. doi: 10.3109/03639045.2012.707209. [PMID: 22817837]
  • Cho-Ming Loi, Dennis A Smith, Deepak Dalvie. Which metabolites circulate?. Drug metabolism and disposition: the biological fate of chemicals. 2013 May; 41(5):933-51. doi: 10.1124/dmd.112.050278. [PMID: 23454828]
  • Daniel Correa, Mark Landau. Ranolazine-induced myopathy in a patient on chronic statin therapy. Journal of clinical neuromuscular disease. 2013 Mar; 14(3):114-6. doi: 10.1097/cnd.0b013e31828525a5. [PMID: 23492463]
  • Qin-You Tan, Huan-De Li, Rong-Hua Zhu, Qi-Zhi Zhang, Jun Zhang, Wen-Xing Peng. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2013 Feb; 13(1):17-25. doi: 10.1007/s40256-013-0006-7. [PMID: 23355361]
  • Richard L Verrier, Vitor P F Pagotto, Alexandre F Kanas, Marcel F Sobrado, Bruce D Nearing, Dewan Zeng, Luiz Belardinelli. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Heart rhythm. 2013 Jan; 10(1):121-7. doi: 10.1016/j.hrthm.2012.09.015. [PMID: 22985658]
  • Robert A Southard, Rachel M Blum, An H Bui, Ron Blankstein. Neurologic adverse effects of ranolazine in an elderly patient with renal impairment. Pharmacotherapy. 2013 Jan; 33(1):e9-13. doi: 10.1002/phar.1152. [PMID: 23307553]
  • Saumya Das, Takeshi Aiba, Michael Rosenberg, Katherine Hessler, Chunyang Xiao, Pablo A Quintero, Filomena G Ottaviano, Ashley C Knight, Evan L Graham, Pontus Boström, Michael R Morissette, Federica del Monte, Michael J Begley, Lewis C Cantley, Patrick T Ellinor, Gordon F Tomaselli, Anthony Rosenzweig. Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation. 2012 Oct; 126(18):2208-19. doi: 10.1161/circulationaha.112.115592. [PMID: 23019294]
  • Marco Panfili, Massimo Iafrate, Filippo Marzot, Silvia Secco, Giovanni De Rosa, Francesca Groppa, Roberto Padrini. Ranolazine-induced severe bladder hypotonia. The Annals of pharmacotherapy. 2012 Sep; 46(9):e24. doi: 10.1345/aph.1r172. [PMID: 22828972]
  • Jing-ya Tang, Wei Wang, Li Li, Chun-gang Zhang, Di-min Wang, Lu Sun. [Analysis of primary metabolites of ranolazine in dog urine by LC-MS(n)]. Yao xue xue bao = Acta pharmaceutica Sinica. 2012 Aug; 47(8):1031-8. doi: NULL. [PMID: 23162900]
  • Marc P Bonaca, Benjamin M Scirica, Marc S Sabatine, Petr Jarolim, Sabina A Murphy, Janna S Chamberlin, Daniel W Rhodes, Paula C Southwick, Eugene Braunwald, David A Morrow. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. Journal of the American College of Cardiology. 2012 Jul; 60(4):332-8. doi: 10.1016/j.jacc.2012.04.023. [PMID: 22813612]
  • Qin-You Tan, Rong-Hua Zhu, Huan-de Li, Ping-Fei Fang, Miao Yan, Qi-Zhi Zhang, Wen-Xing Peng. Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Jul; 901(?):119-24. doi: 10.1016/j.jchromb.2012.06.011. [PMID: 22749688]
  • Arthur Beyder, Peter R Strege, Santiago Reyes, Cheryl E Bernard, Andre Terzic, Jonathan Makielski, Michael J Ackerman, Gianrico Farrugia. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation. 2012 Jun; 125(22):2698-706. doi: 10.1161/circulationaha.112.094714. [PMID: 22565935]
  • Hugues Abriel. Cardiac sodium channel Na(v)1.5 mechanosensitivity is inhibited by ranolazine. Circulation. 2012 Jun; 125(22):2681-3. doi: 10.1161/circulationaha.112.110908. [PMID: 22565937]
  • Chun-Yu Deng, Su-Juan Kuang, Fang Rao, Hui Yang, Xian-Hong Fang, Zhi-Xin Shan, Xiao-Hong Li, Zhi-Ling Zhou, Qiu-Xiong Lin, Min Yang, Shu-Lin Wu, Xi-Yong Yu, Shu-Guang Lin. Effect of ranolazine on rat intrarenal arteries in vitro. European journal of pharmacology. 2012 May; 683(1-3):211-6. doi: 10.1016/j.ejphar.2012.03.010. [PMID: 22449375]
  • Yuan Wang, Xiaoyan Chen, Zuoming Sun, Yong Yang, Ying Zhang, Wanhui Liu, Dafang Zhong. Development and validation of a sensitive LC-MS/MS assay for simultaneous quantitation of ranolazine and its three metabolites in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Mar; 889-890(?):10-6. doi: 10.1016/j.jchromb.2012.01.003. [PMID: 22377406]
  • Yong-Hu Fang, Lin Piao, Zhigang Hong, Peter T Toth, Glenn Marsboom, Peter Bache-Wiig, Jalees Rehman, Stephen L Archer. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. Journal of molecular medicine (Berlin, Germany). 2012 Jan; 90(1):31-43. doi: 10.1007/s00109-011-0804-9. [PMID: 21874543]
  • Hitesh Patni, Michael Gitman, Azzour Hazzan, Kenar D Jhaveri. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. Renal failure. 2012; 34(2):251-3. doi: 10.3109/0886022x.2011.647210. [PMID: 22263871]
  • Chen Dai, Wei Xiao, Yan Liang, Lin Xie, Guangji Wang, Gang Ding, Zhaoqing Meng, Juan Zhang, Tianye Guan, An Kang, Xiao Zheng, Tong Xie, Chunzhu Li, Qijin Zhao, Wenjun Liu, Li Zhao, Jia Xu. Validated liquid chromatography mass spectrometry method for quantitative determination of strictosamide in dog plasma and its application to pharmacokinetic study. Biomedical chromatography : BMC. 2011 Dec; 25(12):1338-42. doi: 10.1002/bmc.1606. [PMID: 21387351]
  • Tuomo Nieminen, Caio A M Tavares, José R M Pegler, Luiz Belardinelli, Richard L Verrier. Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model. Circulation. Cardiovascular interventions. 2011 Oct; 4(5):481-7. doi: 10.1161/circinterventions.111.962852. [PMID: 21953372]
  • Andrew C Zygmunt, Vladislav V Nesterenko, Sridharan Rajamani, Dan Hu, Hector Barajas-Martinez, Luiz Belardinelli, Charles Antzelevitch. Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. American journal of physiology. Heart and circulatory physiology. 2011 Oct; 301(4):H1606-14. doi: 10.1152/ajpheart.00242.2011. [PMID: 21821778]
  • Gong Zhao, Erin Walsh, John C Shryock, Eric Messina, Yuzhi Wu, Dewan Zeng, Xiaobin Xu, Manuel Ochoa, Stephen P Baker, Thomas H Hintze, Luiz Belardinelli. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. Journal of cardiovascular pharmacology. 2011 Jun; 57(6):639-47. doi: 10.1097/fjc.0b013e31821458e8. [PMID: 21633249]
  • Yun Ning, Wei Zhen, Zhuo Fu, Jenny Jiang, Dongmin Liu, Luiz Belardinelli, Arvinder K Dhalla. Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. The Journal of pharmacology and experimental therapeutics. 2011 Apr; 337(1):50-8. doi: 10.1124/jpet.110.176396. [PMID: 21228065]
  • Ann C Hylton, Tanya O Ezekiel. Rhabdomyolysis in a patient receiving ranolazine and simvastatin. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2010 Nov; 67(21):1829-31. doi: 10.2146/ajhp090299. [PMID: 20966146]
  • Dwayne A Pierce, Amber M Reeves-Daniel. Ranolazine-tacrolimus interaction. The Annals of pharmacotherapy. 2010 Nov; 44(11):1844-9. doi: 10.1345/aph.1p297. [PMID: 20876828]
  • Chang-jun Li, Yan-ling Yu, Qing-min Yang, Ying Li, Yu-hong Zhang, Jing-yi Wang. [Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs]. Yao xue xue bao = Acta pharmaceutica Sinica. 2010 Sep; 45(9):1170-6. doi: NULL. [PMID: 21351575]
  • Jeffrey W Chisholm, Allison B Goldfine, Arvinder K Dhalla, Eugene Braunwald, David A Morrow, Ewa Karwatowska-Prokopczuk, Luiz Belardinelli. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes care. 2010 Jun; 33(6):1163-8. doi: 10.2337/dc09-2334. [PMID: 20357382]
  • Syamantak Majumder, M Ilayaraja, Himabindu Reddy Seerapu, Swaraj Sinha, Jamila H Siamwala, Suvro Chatterjee. Chick embryo partial ischemia model: a new approach to study ischemia ex vivo. PloS one. 2010 May; 5(5):e10524. doi: 10.1371/journal.pone.0010524. [PMID: 20479865]
  • David A Morrow, Benjamin M Scirica, Marc S Sabatine, James A de Lemos, Sabina A Murphy, Petr Jarolim, Pierre Theroux, Christophe Bode, Eugene Braunwald. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. Journal of the American College of Cardiology. 2010 Mar; 55(12):1189-1196. doi: 10.1016/j.jacc.2009.09.068. [PMID: 20298924]
  • Arvinder K Dhalla, Wei-Qun Wang, Joan Dow, John C Shryock, Luiz Belardinelli, Anil Bhandari, Robert A Kloner. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. American journal of physiology. Heart and circulatory physiology. 2009 Nov; 297(5):H1923-9. doi: 10.1152/ajpheart.00173.2009. [PMID: 19767532]
  • Lin Wu, Sridharan Rajamani, Hong Li, Craig T January, John C Shryock, Luiz Belardinelli. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart. American journal of physiology. Heart and circulatory physiology. 2009 Sep; 297(3):H1048-57. doi: 10.1152/ajpheart.00467.2009. [PMID: 19592609]
  • Smriti H Deshmukh, Snehal R Patel, Elsa Pinassi, Catalin Mindrescu, Eileen V Hermance, Michael N Infantino, John T Coppola, Cezar S Staniloae. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coronary artery disease. 2009 Aug; 20(5):343-7. doi: 10.1097/mca.0b013e32832a198b. [PMID: 19444092]
  • Kapil Kumar, Bruce D Nearing, Marcelo Carvas, Bruno C G Nascimento, Mariana Acar, Luiz Belardinelli, Richard L Verrier. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. Journal of cardiovascular electrophysiology. 2009 Jul; 20(7):796-802. doi: 10.1111/j.1540-8167.2009.01437.x. [PMID: 19298570]
  • Uttam Bhaumik, Animesh Ghosh, Amlan Kanti Sarkar, Anirbandeep Bose, P Senthamil Selvan, Pinaki Sengupta, Uday Sankar Chakraborty, Debotri Ghosh, Tapan Kumar Pal. Determination of ranolazine in human plasma by LC-MS/MS and its application in bioequivalence study. Journal of pharmaceutical and biomedical analysis. 2008 Dec; 48(5):1404-10. doi: 10.1016/j.jpba.2008.09.033. [PMID: 18986788]
  • Kapil Kumar, Bruce D Nearing, Carlo R Bartoli, Kevin F Kwaku, Luiz Belardinelli, Richard L Verrier. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. Journal of cardiovascular electrophysiology. 2008 Oct; 19(10):1073-9. doi: 10.1111/j.1540-8167.2008.01204.x. [PMID: 18479333]
  • Limei Zhao, Hao Li, Yao Jiang, Riyang Piao, Pengfei Li, Jingkai Gu. Determination of ranolazine in human plasma by liquid chromatographic-tandem mass spectrometric assay. Journal of chromatographic science. 2008 Sep; 46(8):697-700. doi: 10.1093/chromsci/46.8.697. [PMID: 18796225]
  • Sridharan Rajamani, John C Shryock, Luiz Belardinelli. Rapid kinetic interactions of ranolazine with HERG K+ current. Journal of cardiovascular pharmacology. 2008 Jun; 51(6):581-9. doi: 10.1097/fjc.0b013e3181799690. [PMID: 18520952]
  • Ging Kuo Wang, Joanna Calderon, Sho-Ya Wang. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Molecular pharmacology. 2008 Mar; 73(3):940-8. doi: 10.1124/mol.107.041541. [PMID: 18079277]
  • Stephen I Rifkin. Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report. Medscape journal of medicine. 2008; 10(11):264. doi: NULL. [PMID: 19099014]
  • Lei Tian, Juanjuan Jiang, Yiling Huang, Lu Hua, Hong Liu, Yishi Li. Sensitive quantification of ranolazine in human plasma by liquid chromatography--tandem mass spectrometry with positive electrospray ionization. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Feb; 846(1-2):346-50. doi: 10.1016/j.jchromb.2006.08.010. [PMID: 16959552]
  • Kristin Zerumsky, Brian F McBride. Ranolazine in the management of chronic stable angina. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2006 Dec; 63(23):2331-8. doi: 10.2146/ajhp060042. [PMID: 17106005]
  • Gong Zhao, Eric Messina, Xiaobin Xu, Manuel Ochoa, Sobrina Serpillon, John Shryock, Luiz Belardinelli, Thomas H Hintze. Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs. European journal of pharmacology. 2006 Jul; 541(3):171-6. doi: 10.1016/j.ejphar.2006.05.016. [PMID: 16777088]
  • Sandra Fredj, Kevin J Sampson, Huajun Liu, Robert S Kass. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. British journal of pharmacology. 2006 May; 148(1):16-24. doi: 10.1038/sj.bjp.0706709. [PMID: 16520744]
  • Yan Liang, Lin Xie, Xiao-Dong Liu, Wei-Dong Chen, Tong Lu, Ye Xiong, Guang-Ji Wang. Simple, sensitive and rapid liquid chromatography/atmospheric pressure chemical ionization mass spectrometric method for the quantitation of Ranolazine in rat plasma. Rapid communications in mass spectrometry : RCM. 2006; 20(4):523-8. doi: 10.1002/rcm.2331. [PMID: 16419025]
  • Markus Jerling. Clinical pharmacokinetics of ranolazine. Clinical pharmacokinetics. 2006; 45(5):469-91. doi: 10.2165/00003088-200645050-00003. [PMID: 16640453]
  • M Asif A Siddiqui, Susan J Keam. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2006; 66(5):693-710. doi: 10.2165/00003495-200666050-00010. [PMID: 16620147]
  • M Asif A Siddiqui, Susan J Keam. Spotlight on ranolazine in chronic stable angina pectoris. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2006; 6(5):357-9. doi: 10.2165/00129784-200606050-00009. [PMID: 17083271]
  • Pirouz Parang, Bramah Singh, Rohit Arora. Metabolic modulators for chronic cardiac ischemia. Journal of cardiovascular pharmacology and therapeutics. 2005 Dec; 10(4):217-23. doi: 10.1177/107424840501000402. [PMID: 16382258]
  • Markus Jerling, Hisham Abdallah. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clinical pharmacology and therapeutics. 2005 Sep; 78(3):288-97. doi: 10.1016/j.clpt.2005.05.004. [PMID: 16153399]
  • Hisham Abdallah, Markus Jerling. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. Journal of clinical pharmacology. 2005 Jul; 45(7):802-9. doi: 10.1177/0091270005276739. [PMID: 15951470]
  • Markus Jerling, Bee-Lian Huan, Kwan Leung, Nancy Chu, Hisham Abdallah, Ziad Hussein. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. Journal of clinical pharmacology. 2005 Apr; 45(4):422-33. doi: 10.1177/0091270004273992. [PMID: 15778423]
  • Charles Antzelevitch, Luiz Belardinelli, Lin Wu, Heather Fraser, Andrew C Zygmunt, Alexander Burashnikov, José M Di Diego, Jeffrey M Fish, Jonathan M Cordeiro, Robert J Goodrow, Fabiana Scornik, Guillermo Perez. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. Journal of cardiovascular pharmacology and therapeutics. 2004 Sep; 9 Suppl 1(?):S65-83. doi: 10.1177/107424840400900106. [PMID: 15378132]
  • Charles Antzelevitch, Luiz Belardinelli, Andrew C Zygmunt, Alexander Burashnikov, José M Di Diego, Jeffrey M Fish, Jonathan M Cordeiro, George Thomas. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004 Aug; 110(8):904-10. doi: 10.1161/01.cir.0000139333.83620.5d. [PMID: 15302796]
  • Bernard R Chaitman, Sandra L Skettino, John O Parker, Peter Hanley, Jaroslav Meluzin, Jerzy Kuch, Carl J Pepine, Whedy Wang, Jeanenne J Nelson, David A Hebert, Andrew A Wolff. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. Journal of the American College of Cardiology. 2004 Apr; 43(8):1375-82. doi: 10.1016/j.jacc.2003.11.045. [PMID: 15093870]
  • M F McCarty. A shift in myocardial substrate, improved endothelial function, and diminished sympathetic activity may contribute to the anti-anginal impact of very-low-fat diets. Medical hypotheses. 2004; 62(1):62-71. doi: 10.1016/s0306-9877(03)00232-9. [PMID: 14729006]
  • X D Liu, L Xie, Y Liang, L Li, T Lu. Gender difference in ranolazine pharmacokinetics in rats. European journal of drug metabolism and pharmacokinetics. 2003 Apr; 28(2):119-23. doi: 10.1007/bf03190499. [PMID: 12877569]
  • K Zacharowski, B Blackburn, C Thiemermann. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. European journal of pharmacology. 2001 Apr; 418(1-2):105-10. doi: 10.1016/s0014-2999(01)00920-7. [PMID: 11334871]
  • M Spedding, J P Tillement, D Morin, A Le Ridant. [Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine]. Therapie. 1999 Sep; 54(5):627-35. doi: ". [PMID: 10667101]
  • C J Pepine, A A Wolff. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. The American journal of cardiology. 1999 Jul; 84(1):46-50. doi: 10.1016/s0002-9149(99)00190-3. [PMID: 10404850]
  • H Matsumura, A Hara, H Hashizume, K Maruyama, Y Abiko. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Japanese journal of pharmacology. 1998 May; 77(1):31-9. doi: 10.1254/jjp.77.31. [PMID: 9639058]
  • A Aaker, J G McCormack, T Hirai, T I Musch. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. Journal of cardiovascular pharmacology. 1996 Sep; 28(3):353-62. doi: 10.1097/00005344-199609000-00002. [PMID: 8877580]